Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Current Assets: 2016-2024

Historic Current Assets for Rocket Pharmaceuticals (RCKT) over the last 9 years, with Dec 2024 value amounting to $378.2 million.

  • Rocket Pharmaceuticals' Current Assets fell 5.82% to $227.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $227.7 million, marking a year-over-year decrease of 5.82%. This contributed to the annual value of $378.2 million for FY2024, which is 0.01% down from last year.
  • Per Rocket Pharmaceuticals' latest filing, its Current Assets stood at $378.2 million for FY2024, which was down 0.01% from $378.2 million recorded in FY2023.
  • In the past 5 years, Rocket Pharmaceuticals' Current Assets ranged from a high of $487.3 million in FY2020 and a low of $364.1 million during FY2022.
  • Its 3-year average for Current Assets is $373.5 million, with a median of $378.2 million in 2024.
  • In the last 5 years, Rocket Pharmaceuticals' Current Assets spiked by 58.36% in 2020 and then decreased by 19.55% in 2021.
  • Over the past 5 years, Rocket Pharmaceuticals' Current Assets (Yearly) stood at $487.3 million in 2020, then declined by 19.55% to $392.1 million in 2021, then decreased by 7.14% to $364.1 million in 2022, then increased by 3.89% to $378.2 million in 2023, then fell by 0.01% to $378.2 million in 2024.